DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,254 filers reported holding DANAHER CORPORATION in Q3 2018. The put-call ratio across all filers is 1.05 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $82,186,619 | +2.9% | 331,264 | -0.4% | 1.38% | +7.0% |
| Q2 2023 | $79,839,364 | -6.4% | 332,664 | -1.7% | 1.29% | -9.2% |
| Q1 2023 | $85,328,861 | -7.0% | 338,553 | -2.1% | 1.42% | -7.5% |
| Q4 2022 | $91,766,670 | -6.8% | 345,741 | -9.3% | 1.53% | -15.7% |
| Q3 2022 | $98,481,000 | -1.6% | 381,281 | -3.4% | 1.82% | +7.1% |
| Q2 2022 | $100,112,000 | -15.6% | 394,889 | -2.3% | 1.70% | +1.6% |
| Q1 2022 | $118,597,000 | -15.9% | 404,314 | -5.7% | 1.67% | -10.8% |
| Q4 2021 | $140,996,000 | +1.0% | 428,548 | -6.5% | 1.88% | -6.1% |
| Q3 2021 | $139,542,000 | +9.0% | 458,357 | -3.9% | 2.00% | +11.3% |
| Q2 2021 | $128,013,000 | +17.3% | 477,021 | -1.6% | 1.80% | +6.2% |
| Q1 2021 | $109,131,000 | -0.9% | 484,854 | -2.2% | 1.69% | -8.3% |
| Q4 2020 | $110,121,000 | -0.1% | 495,729 | -3.2% | 1.84% | -15.5% |
| Q3 2020 | $110,234,000 | +17.2% | 511,932 | -3.8% | 2.18% | +8.0% |
| Q2 2020 | $94,095,000 | +26.1% | 532,124 | -1.3% | 2.02% | +2.9% |
| Q1 2020 | $74,640,000 | -12.7% | 539,266 | -3.1% | 1.96% | +23.5% |
| Q4 2019 | $85,450,000 | +5.2% | 556,747 | -1.0% | 1.59% | -1.7% |
| Q3 2019 | $81,206,000 | -0.4% | 562,253 | -1.5% | 1.62% | +1.8% |
| Q2 2019 | $81,567,000 | +7.1% | 570,720 | -1.1% | 1.59% | +0.6% |
| Q1 2019 | $76,157,000 | +28.4% | 576,861 | +0.3% | 1.58% | +12.9% |
| Q4 2018 | $59,294,000 | -1.7% | 575,001 | +3.6% | 1.40% | +18.1% |
| Q3 2018 | $60,290,000 | +13.4% | 554,847 | +3.0% | 1.18% | +5.1% |
| Q2 2018 | $53,173,000 | +0.1% | 538,841 | -0.7% | 1.13% | -2.4% |
| Q1 2018 | $53,107,000 | +4.7% | 542,410 | -0.8% | 1.16% | +7.9% |
| Q4 2017 | $50,740,000 | +9.1% | 546,647 | +0.8% | 1.07% | +0.3% |
| Q3 2017 | $46,519,000 | -1.0% | 542,307 | -2.6% | 1.07% | -3.7% |
| Q2 2017 | $47,006,000 | -1.1% | 557,010 | +0.2% | 1.11% | -6.4% |
| Q1 2017 | $47,537,000 | +11.8% | 555,791 | +1.8% | 1.18% | +9.2% |
| Q4 2016 | $42,509,000 | -2.3% | 546,107 | -1.6% | 1.08% | -6.6% |
| Q3 2016 | $43,503,000 | -23.2% | 554,961 | -1.0% | 1.16% | -28.7% |
| Q2 2016 | $56,636,000 | +4.8% | 560,754 | -1.6% | 1.63% | +10.0% |
| Q1 2016 | $54,051,000 | – | 569,797 | – | 1.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
| WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
| Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
| Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
| CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
| Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
| Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
| Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
| Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
| Third Point | 3,570,000 | $494,124,000 | 7.88% |